Novanta Lands $45M Bet: Smart Money Sees Value
💡 Key Takeaway
A major institutional investor is betting $45 million that Novanta's underperformance is temporary and its medical/industrial technology will drive recovery.
The $45 Million Vote of Confidence
On February 13, 2026, ACK Asset Management LLC made a significant move by establishing a new position in Novanta (NOVT), acquiring 375,000 shares worth approximately $44.62 million. This substantial investment represents 5.6% of the fund's total assets under management, making it one of their larger portfolio allocations.
The timing is particularly interesting because Novanta's stock has been essentially flat over the past year, actually declining 5.7% while significantly underperforming the S&P 500 by nearly 19 percentage points. Despite this weak price action, the company continues to generate solid financial results with $960 million in trailing revenue and $52.8 million in net income.
Novanta specializes in photonics, vision, and precision motion components for medical and industrial equipment manufacturers. The company serves OEMs in medical technology, life sciences, and advanced industrial applications worldwide with highly engineered solutions.
ACK Asset Management's portfolio shows a clear tilt toward industrial and infrastructure names, with top holdings including Materion, Granite Construction, and Advanced Drainage Systems. This new Novanta position fits their established investment theme while representing a conviction bet on a company that has disappointed the broader market recently.
Reading Between the Lines of a Smart Money Move
This $45 million investment matters because institutional moves of this size typically signal deep research and conviction. ACK isn't just dipping a toe in - they're making Novanta a meaningful part of their portfolio despite the stock's recent underperformance, suggesting they see a disconnect between price and value.
The investment thesis appears to center on Novanta's recovery potential as medical and advanced industrial demand improves. While the stock has languished, the company's fundamentals remain solid with Q3 revenue up 1.4% year-over-year and adjusted EBITDA margins at a healthy 23.4%.
Novanta's guidance for 2025 calls for $975-979 million in revenue and $222-225 million in adjusted EBITDA, indicating management expects stable performance. The company's niche in precision components for growing medical and industrial markets provides a durable competitive advantage that may not be fully appreciated by the market.
Bobby Insight
Follow the smart money - Novanta represents an attractive opportunity with institutional backing.
ACK's substantial investment suggests they've identified value the market is missing. Novanta's solid fundamentals, niche technology leadership, and reasonable valuation create a compelling risk-reward profile. The main risk is timing - recovery in medical/industrial demand may take longer than expected.
What This Means for Me
